Advertisement
Canada markets open in 4 hours 53 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7310
    -0.0010 (-0.14%)
     

  • CRUDE OIL

    83.31
    -0.05 (-0.06%)
     

  • Bitcoin CAD

    91,271.29
    +836.34 (+0.92%)
     

  • CMC Crypto 200

    1,436.55
    +12.45 (+0.87%)
     

  • GOLD FUTURES

    2,331.70
    -10.40 (-0.44%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,717.00
    +110.25 (+0.63%)
     

  • VOLATILITY

    15.77
    +0.08 (+0.51%)
     

  • FTSE

    8,087.37
    +42.56 (+0.53%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6839
    +0.0003 (+0.04%)
     

Stocks in play: Resverlogix Corp.

Baystreet.ca
Updated

Is seeking a partnership with an existing stakeholder in the ongoing fight against HIV-1. The most recent publication titled: “The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation,” in Nature’s Acta Pharmacologica Sinica (2018) 0:1–13; demonstrated apabetalone’s abilities to expose and reactivate latent HIV-1 reservoirs, induce HIV-1 latent cell death, and reduce the side effects of standard of care. Resverlogix Corp. shares T.RVX are trading down $0.12 at $1.28.